Literature DB >> 15003789

Osteoclastogenesis is decreased by cysteine proteinase inhibitors.

Monica Brage1, Anita Lie, Maria Ransjö, Franciszek Kasprzykowski, Regina Kasprzykowska, Magnus Abrahamson, Anders Grubb, Ulf H Lerner.   

Abstract

The effects of cystatin C and other cysteine proteinase inhibitors on osteoclast formation and differentiation have been investigated. Cystatin C decreased osteoclast formation stimulated by parathyroid hormone (PTH), 1,25(OH)2-vitamin D3 or interleukin-6 (IL-6) (in the presence of its soluble receptor) as assessed by the number of tartrate-resistant acid phosphatase (TRAP+) multinucleated cells in mouse bone marrow cultures. The inhibitory effect was associated with decreased mRNA expression for the calcitonin receptor as well as decreased number of specific binding sites for 125I-calcitonin, and without any effect on the mRNA expression of receptor activator of nuclear factor kappaB (NF-kappaB) ligand (RANKL). Similarly, the cysteine proteinase inhibitors leupeptin, E-64 and benzyloxycarbonyl-Phe-Ala-diazomethane (Z-FA-CHN2) decreased PTH-stimulated formation of TRAP+ multinucleated cells and binding of 125I-calcitonin. A peptidyl derivative synthesized to mimic part of the proteinase-binding site of cystatin C (benzyloxycarbonyl-Arg-Leu-Val-Gly-diazomethane, or Z-RLVG-CHN2) also decreased PTH-stimulated osteoclast formation. In a 9-day culture, addition of cystatin C during the last 5 days was sufficient to cause substantial inhibition of osteoclast formation. Cystatin C-induced decrease of osteoclast formation was associated with enhanced number of F4/80-positive macrophages and increased mRNA expression of the macrophage receptor c-fms in the bone marrow culture. Osteoclast formation in mouse bone marrow cultures as well as in mouse spleen cell cultures, stimulated by macrophage colony-stimulating factor (M-CSF) and RANKL was also decreased by different cysteine proteinase inhibitors. In addition, cystatin C inhibited M-CSF/RANKL induction of calcitonin receptor mRNA in spleen cell cultures. The inhibitory effect by cystatin C in spleen cells was associated with decreased mRNA expression of RANK and the transcription factor NFAT2. It is concluded that cysteine proteinase inhibitors decrease formation of osteoclasts by interfering at a late stage of pre-osteoclast differentiation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15003789     DOI: 10.1016/j.bone.2003.11.018

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  11 in total

1.  Schistosoma japonicum cystatin attenuates murine collagen-induced arthritis.

Authors:  Fang Liu; Weisheng Cheng; Faustina Pappoe; Xiaodong Hu; Huiqin Wen; Qingli Luo; Shushu Wang; Fang Deng; Yuanyuan Xie; Yuanhong Xu; Jilong Shen
Journal:  Parasitol Res       Date:  2016-07-08       Impact factor: 2.289

2.  Rapidly assessing changes in bone mineral balance using natural stable calcium isotopes.

Authors:  Jennifer L L Morgan; Joseph L Skulan; Gwyneth W Gordon; Stephen J Romaniello; Scott M Smith; Ariel D Anbar
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-31       Impact factor: 11.205

3.  Causal Effects of Genetically Predicted Cystatin C on Osteoporosis: A Two-Sample Mendelian Randomization Study.

Authors:  Jiaqin Yuan; Lipeng Peng; Fujun Luan; Jie Li; Jinglin Zhang; Wei Jiang; Wenting Wang
Journal:  Front Genet       Date:  2022-05-02       Impact factor: 4.772

Review 4.  Macrophage immunomodulation in chronic osteolytic diseases-the case of periodontitis.

Authors:  Corneliu Sima; Ana Viniegra; Michael Glogauer
Journal:  J Leukoc Biol       Date:  2018-11-19       Impact factor: 4.962

5.  Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C.

Authors:  Francesca M Tumminello; Giuseppe Badalamenti; Lorena Incorvaia; Fabio Fulfaro; Calogero D'Amico; Gaetano Leto
Journal:  Med Oncol       Date:  2008-05-07       Impact factor: 3.064

6.  Cystatin C influences the autoimmune but not inflammatory response to cartilage type II collagen leading to chronic arthritis development.

Authors:  Alexandra Bäcklund; Meirav Holmdahl; Ragnar Mattsson; Katarina Håkansson; Veronica Lindström; Kutty Selva Nandakumar; Anders Grubb; Rikard Holmdahl
Journal:  Arthritis Res Ther       Date:  2011-03-28       Impact factor: 5.156

7.  Cystatin C as a potential predictor of osteoprotegerin levels in healthy men, a cross-sectional, observational study.

Authors:  Eva Kulcsar-Jakab; Zsofia Petho; Zoltan Pap; Edit Kalina; Roza Foldesi; Adam Balogh; Peter Antal-Szalmas; Harjit Pal Bhattoa
Journal:  BMC Musculoskelet Disord       Date:  2015-08-28       Impact factor: 2.362

8.  The newly discovered cytokine IL-34 is expressed in gingival fibroblasts, shows enhanced expression by pro-inflammatory cytokines, and stimulates osteoclast differentiation.

Authors:  Elisabeth A Boström; Pernilla Lundberg
Journal:  PLoS One       Date:  2013-12-10       Impact factor: 3.240

Review 9.  Pharmacological Therapies for the Management of Inflammatory Bone Resorption in Periodontal Disease: A Review of Preclinical Studies.

Authors:  Angelica Leticia Reis Pavanelli; Bruna Silva de Menezes; Erica Bianca Barbosa Pereira; Fabio Assuncao de Souza Morais; Joni Augusto Cirelli; Rafael Scaf de Molon
Journal:  Biomed Res Int       Date:  2022-05-02       Impact factor: 3.246

10.  Cysteine cathepsin activity suppresses osteoclastogenesis of myeloid-derived suppressor cells in breast cancer.

Authors:  Laura E Edgington-Mitchell; Jai Rautela; Hendrika M Duivenvoorden; Krishnath M Jayatilleke; Wouter A van der Linden; Martijn Verdoes; Matthew Bogyo; Belinda S Parker
Journal:  Oncotarget       Date:  2015-09-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.